Novo Nordisk A/S Files for Regulatory Approval of the Ultra-Long-Acting Insulin Degludec in Japan

BAGSVAERD, DENMARK--(Marketwire - December 22, 2011) -

Novo Nordisk today announced the submission to the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, of a new drug application for the approval of ultra-long-acting insulin Degludec. This new-generation basal insulin has been developed for the treatment of people with type 1 and type 2 diabetes.

Company Announcemen no 80 / 2011: http://hugin.info/2013/R/1573350/489678.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1573350]